SLC5A2 and diabetic kidney disease: Interestingly however, pooled analyses from all phase 3 trials with dapagliflozin and empagliflozin have shown that the efficacy of SGLT-2 inhibitors on other cardiovascular and renal risk factors such as blood pressure, body weight, albuminuria, and uric acid is not attenuated in people with DKD [66–68].